On Tuesday, Astrazeneca plc ADR (NASDAQ: AZN) was -0.15% drop from the session before settling in for the closing price of $77.44. A 52-week range for AZN has been $60.47 – $87.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 16.24% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 12.97%. With a float of $3.10 billion, this company’s outstanding shares have now reached $3.10 billion.
In an organization with 89900 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 78.24%, operating margin of 18.87%, and the pretax margin is 15.8%.
Astrazeneca plc ADR (AZN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Astrazeneca plc ADR stocks. The insider ownership of Astrazeneca plc ADR is 0.03%, while institutional ownership is 16.30%.
Astrazeneca plc ADR (AZN) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted 0.87 earnings per share (EPS) during the time that was better than consensus figure (set at 0.84) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.57% during the next five years compared to 17.72% growth over the previous five years of trading.
Astrazeneca plc ADR (NASDAQ: AZN) Trading Performance Indicators
You can see what Astrazeneca plc ADR (AZN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.88. Likewise, its price to free cash flow for the trailing twelve months is 24.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.06, a number that is poised to hit 1.03 in the next quarter and is forecasted to reach 4.73 in one year’s time.
Technical Analysis of Astrazeneca plc ADR (AZN)
Let’s dig in a bit further. During the last 5-days, its volume was 2.56 million. That was inferior than the volume of 5.04 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 53.90%. Additionally, its Average True Range was 0.93.
During the past 100 days, Astrazeneca plc ADR’s (AZN) raw stochastic average was set at 8.97%, which indicates a significant decrease from 33.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 12.83% in the past 14 days, which was lower than the 17.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $80.82, while its 200-day Moving Average is $74.57. However, in the short run, Astrazeneca plc ADR’s stock first resistance to watch stands at $77.59. Second resistance stands at $77.87. The third major resistance level sits at $78.32. If the price goes on to break the first support level at $76.86, it is likely to go to the next support level at $76.41. Assuming the price breaks the second support level, the third support level stands at $76.13.
Astrazeneca plc ADR (NASDAQ: AZN) Key Stats
There are 3,100,512K outstanding shares of the company, which has a market capitalization of 239.74 billion. As of now, sales total 45,811 M while income totals 5,955 M. Its latest quarter income was 12,938 M while its last quarter net income were 1,927 M.
